GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
380
c/survodutide·posted 1 months ago by u/marisol_frisk

glucagon is the most under-discussed thing in c/scamalerts

Paper Clean Column ×3

Something I noticed reading old threads that I have not seen said out loud.

The advice on hepatic fat in this community changed substantially around the start of last year, and nobody went back and updated the older posts. So depending on which thread the search engine hands you, you get two contradictory answers with the same confidence.

I have listed what I think the current consensus is below. Correct me — that is the point of posting it.

488 up / 108 down82% upvoted24 commentsid t96fj99 Jun 2026

24 comments

19 in this archive, depth 5

best — the order this archive was captured in

u/elin_ferrari47 points·1 months ago

the MASH indication changes the risk calculus

replysharereportpermalink
u/marisol_friskOP21 points·1 months ago

The confident tone is doing a lot of work that the evidence is not.

replysharereportpermalink
u/border_paperwork11 points·1 months ago

Sceptical. If this were true we would see it reflected in the data and we do not.

replysharereportpermalink
u/marisol_friskOP18 points·1 months ago

MASH claims need the trial and the biopsy endpoint

replysharereportpermalink
u/farid_kuipers10 points·1 months ago

the GLP-1/glucagon dual is hepatic fat, different from GIP/GLP-1

replysharereportpermalink
u/titration_marshalmod · c/semaglutide13 points·1 months ago

do not generalise from tirzepatide

replysharereportpermalink
u/patient_labslip_log31 points·1 months ago

Respectfully this is a sample of one presented as a finding.

replysharereportpermalink
u/nora_ramos23 points·1 months ago

Yeah, glucagon co-agonism is genuinely different.

replysharereportpermalink
u/nora_ramos-7 points·1 months ago

Phase 18 or 11?

replysharereportpermalink
u/marisol_friskOP16 points·1 months ago

Stalled for 16 weeks, changed nothing, and it started moving again on week 73.

replysharereportpermalink
u/paper_trail_paulavetting13 points·1 months ago·edited

Not convinced. The evidence does not support that reading.

replysharereportpermalink
u/camila_trevino8 points·1 months ago

glucagon co-agonism has a different safety story

replysharereportpermalink
u/liver_enzyme_liz13 points·1 months ago·edited

Mechanistically the bit that matters is glucagon. It explains most of the early profile and a decent chunk of the outcome.

replysharereportpermalink
u/teodor_szabo9 points·1 months ago

the MASH indication changes the risk calculus

replysharereportpermalink
u/preservative_free_p3 points·1 months ago·edited

That is net peptide content, not purity. Different number, different meaning.

replysharereportpermalink
u/heart_rate_bump2 points·1 months ago·edited

phase 8 data is interesting, phase 25 will be different

replysharereportpermalink
u/cesar_ivaturi1 point·1 months ago·edited

You have restated the marketing copy. What is the actual substance here.

replysharereportpermalink
u/incretin_ivypharmacology5 points·1 months ago

the heart rate signal is real in the data

replysharereportpermalink
u/clara_restrepo1 point·1 months ago

Phase 15 or 13?

replysharereportpermalink
Permalinked branches
Deep branches get their own page so a single reply chain can be linked and read on its own.
About c/survodutide

Survodutide-specific discussion: glucagon-receptor co-agonism, the hepatic fat and MASH resolution data, and how the side-effect profile compares with GIP-based dual agonism. Small community, high signal.

12kmembers
62submissions
Feb 2024created
submissions / month, last year
Sponsored

Sigma-Aldrich Standards

Certified reference materials for peptide identity and purity work.

sigmaaldrich.com
More in c/survodutide
c/survodutide rules
  1. Glucagon co-agonism has a distinct safety story. Do not generalise from tirzepatide.
  2. MASH claims need the trial and the biopsy endpoint.
  3. Not approved. Descriptive posts only.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Full rules and how they are enforced →
Moderators
u/incretin_ivyu/liver_enzyme_lizu/trialwatch_theo
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.

Full disclaimer →